Cardiovascular Diabetology (Apr 2022)
Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes
- Oliver Schnell,
- Tadej Battelino,
- Richard Bergenstal,
- Matthias Blüher,
- Michael Böhm,
- Frank Brosius,
- Richard D. Carr,
- Antonio Ceriello,
- Thomas Forst,
- Francesco Giorgino,
- Bruno Guerci,
- Hiddo J. L. Heerspink,
- Baruch Itzhak,
- Linong Ji,
- Mikhail Kosiborod,
- Nebojša Lalić,
- Michael Lehrke,
- Nikolaus Marx,
- Michael Nauck,
- Helena W. Rodbard,
- Giuseppe M. C. Rosano,
- Peter Rossing,
- Lars Rydén,
- Francesca Santilli,
- Petra-Maria Schumm-Draeger,
- Per Olav Vandvik,
- Tina Vilsbøll,
- Christoph Wanner,
- Carol Wysham,
- Eberhard Standl
Affiliations
- Oliver Schnell
- Forschergruppe Diabetes e. V., Helmholtz Center Munich
- Tadej Battelino
- University Medical Center
- Richard Bergenstal
- International Diabetes Center at Park Nicollet, Health Partners
- Matthias Blüher
- Department of Medicine, University of Leipzig
- Michael Böhm
- Klinik für Innere Medizin III, Universitätsklinikum des Saarlandes, Saarland University
- Frank Brosius
- College of Medicine, University of Arizona
- Richard D. Carr
- University College London
- Antonio Ceriello
- IRCCS MultiMedica
- Thomas Forst
- CRS Clinical Research Services Mannheim GmbH
- Francesco Giorgino
- Department of Emergency and Organ Transplantation, University of Bari Aldo Moro
- Bruno Guerci
- Department of Endocrinology Diabetology and Nutrition, Nancy University Hospital
- Hiddo J. L. Heerspink
- Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen
- Baruch Itzhak
- Clalit Health Services and Technion Faculty of Medicine
- Linong Ji
- Peking University People’s Hospital
- Mikhail Kosiborod
- Cardiometabolic Center of Excellence, University of Missouri-Kansas City
- Nebojša Lalić
- Faculty of Medicine, Clinic for Endocrinology, Diabetes and Metabolic Diseases, University Clinical Center of Serbia, University of Belgrade
- Michael Lehrke
- Department of Internal Medicine I, University Hospital Aachen
- Nikolaus Marx
- Department of Internal Medicine I, University Hospital Aachen
- Michael Nauck
- Diabetes Division, Katholisches Klinikum Bochum, St. Josef-Hospital, Ruhr University Bochum
- Helena W. Rodbard
- Endocrine and Metabolic Consultants
- Giuseppe M. C. Rosano
- Department of Medical Sciences, IRCCS
- Peter Rossing
- Steno Diabetes Center Copenhagen
- Lars Rydén
- Department of Medicine K2, Karolinska Institute
- Francesca Santilli
- Department of Medicine and Aging, Hospital and, University of Chieti
- Petra-Maria Schumm-Draeger
- Centre Internal Medicine Fünf Höfe
- Per Olav Vandvik
- Department of Medicine, Lovisenberg Diaconal Hospital
- Tina Vilsbøll
- Steno Diabetes Center Copenhagen
- Christoph Wanner
- University Hospital of Würzburg
- Carol Wysham
- Section of Endocrinology and Metabolism, MultiCare Rockwood Clinic
- Eberhard Standl
- Forschergruppe Diabetes e. V., Helmholtz Center Munich
- DOI
- https://doi.org/10.1186/s12933-022-01481-0
- Journal volume & issue
-
Vol. 21,
no. 1
pp. 1 – 16
Abstract
Abstract The 7th Cardiovascular Outcome Trial (CVOT) Summit on Cardiovascular, Renal, and Glycemic Outcomes, was held virtually on November 18–19, 2021. Pursuing the tradition of the previous summits, this reference congress served as a platform for in-depth discussion and exchange on recently completed CVOTs. This year’s focus was placed on the outcomes of EMPEROR-Preserved, FIGARO-DKD, AMPLITUDE-O, SURPASS 1–5, and STEP 1–5. Trial implications for diabetes and obesity management and the impact on new treatment algorithms were highlighted for endocrinologists, diabetologists, cardiologists, nephrologists, and general practitioners. Discussions evolved from outcome trials using SGLT2 inhibitors as therapy for heart failure, to CVOTs with nonsteroidal mineralocorticoid receptor antagonists and GLP-1 receptor agonists. Furthermore, trials for glycemic and overweight/obesity management, challenges in diabetes management in COVID-19, and novel guidelines and treatment strategies were discussed. Trial registration The 8th Cardiovascular Outcome Trial Summit will be held virtually on November 10–11, 2022 ( http://www.cvot.org )
Keywords
